Education
About Us
Working with TipRanks
Follow Us
Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
IMDX Stock Chart & Stats
$5.92
--
Market closed
$5.92
--
Day’s Range― - ―
52-Week Range$1.92 - $5.32
Previous CloseN/A
VolumeN/A
Average Volume (3M)42.75K
Market Cap
$169.57M
Enterprise Value$75.80M
Total Cash (Recent Filing)$24.29M
Total Debt (Recent Filing)$3.37M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Nov 06, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding28,619,750
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue17.81
Enterprise Value/Gross Profit28.07
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$6.13Price Target Upside3.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical Trials And FDA ApprovalIMDX has proceeded into Phase 3 which includes a ~125 patient validation trial and still expects to sign-on at least 20 transplant centers in the US and Germany by the end of 2025.
Partnership And Market ExpansionIMDX remains confident in its partnership with BioRad, whereby BioRad and IMDX will comarket GraftAssure inside the US/Germany, and BioRad will take the commercial lead in the ROW.
Product Launch And AdoptionIMDX's launch of GraftAssureIQ research use only test (RUO) is going well and IMDX continues to sign on transplant centers ahead of its GraftAssureDx Kidney kitted test launch in mid-2026 upon FDA clearance.
Bears Say
Analyst RatingsIt will take time for IMDX to advance its work and impact numbers, and as a result, the analyst reiterates a Neutral rating on IMDX.
Cash Management And Financial OutlookIMDX ended 2Q25 with ~$24M cash and continues to make progress in managing its cash burn which management expects to remain at ~$6M per quarter until the GraftAssureDx commercial launch.
Insight Molecular Diagnostics News
IMDX FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was $1.92 and its highest was $5.32 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $169.57M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Nov 06, 2025 which is in 5 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on Aug 11, 2025. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.23 by -$0.07.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.21.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 28,619,750 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.23. Following the earnings report the stock price went down -3.831%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in IMDX
Insight Molecular Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.13 (3.55% Upside)
$6.13 (3.55% Upside)
Hedge Fund Trend
Decreased
By 44.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.71%
12-Months-Change
Fundamentals
Return on Equity
-532.89%
Trailing 12-Months
Asset Growth
-32.39%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
Insight Molecular Diagnostics (IMDX) is a biotechnology company specializing in the development of molecular diagnostic tests for infectious diseases and other health conditions. The company focuses on leveraging advanced technologies to improve patient outcomes through accurate and timely diagnostics. IMDX's core products include a range of molecular assays designed for use in clinical laboratories, enabling healthcare providers to make informed decisions based on precise genetic and pathogen information.
IMDX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company making solid progress with its FDA submission and assay improvements, supported by strong engagement with transplant centers and a high positive predictive value achievement. However, these positive developments are tempered by challenges in revenue generation and clinical trial enrollment.View all IMDX earnings summariesIMDX Stock 12 Month Forecast
Average Price Target
$6.13
▲(3.55% Upside)
Technical Analysis
Atossa Therapeutics
―
MacroGenics
―
Aziyo Biologics
―
Surrozen
―
Telomir Pharmaceuticals, Inc.
―